{"id":393,"date":"2020-07-25T08:20:48","date_gmt":"2020-07-25T08:20:48","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=393"},"modified":"2020-07-25T08:20:48","modified_gmt":"2020-07-25T08:20:48","slug":"23-july-2020-tocilizumab-clinical-status-improved-within-24-hours-in-39patients","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/23-july-2020-tocilizumab-clinical-status-improved-within-24-hours-in-39patients\/","title":{"rendered":"(23 July 2020) Tocilizumab- Clinical status improved within 24 hours in 39%patients"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study<\/p>\n<p class=\"\">https:\/\/doi.org\/10.1080\/14787210.2020.1800453<\/p>\n<p class=\"\">This retrospective study included patients with severe COVID-19 requiring oxygen therapy who received tocilizumab in seven centers across Poland. We assessed on-treatment changes in clinical status and inflammatory markers.&nbsp; Twenty-eight patients were included (19 male), with a mean age of 61.7+\/-12.4 years. The mean time from symptom onset to the first tocilizumab dose was 10.5 +\/- 5.7 days. Clinical status improved within 24 hours in 11 (39%) patients, within one week in 23 (82%) patients, and within two weeks in 25 (89%); one (4%) patient showed no change and two (7%) patients died. Sixteen patients (57%) no longer needed oxygen therapy within a week (p &lt;0.001). The serum concentrations of C-reactive protein, procalcitonin, and fibrinogen decreased significantly (p &lt;\/=0.001). Lung changes improved in 21 (84%) patients within two weeks of treatment; 19 had minimal or no changes upon final examination. Tocilizumab can control the symptoms of severe COVID-19 by reducing the inflammatory response and rapidly improves the clinical status in most patients.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study https:\/\/doi.org\/10.1080\/14787210.2020.1800453 This retrospective study included patients with severe COVID-19 requiring oxygen therapy who received tocilizumab in seven centers across Poland. We assessed on-treatment changes in clinical status and inflammatory markers.&nbsp;&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/23-july-2020-tocilizumab-clinical-status-improved-within-24-hours-in-39patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(23 July 2020) Tocilizumab- Clinical status improved within 24 hours in 39%patients&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/393"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=393"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/393\/revisions"}],"predecessor-version":[{"id":394,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/393\/revisions\/394"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=393"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=393"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}